Angiotensin Receptor Neprilysin Inhibitors-2019 Update.

Cardiovascular Drugs and Therapy
George Chalikias, Dimitrios Tziakas

Abstract

An abundance of new data regarding the use of the novel drug compound sacubitril/valsartan in chronic heart failure (CHF) patients is published every year since the initial publication of the PARADIGM-HF study in 2014. This review summarises the most recent evidence (2019 and onwards) of sacubitril/valsartan in CHF patients as well as provides a critical appraisal of these data. New data are grouped in categories such as real-world data, randomised controlled trials, surrogate end-points, cost-effectiveness, use of sacubitril/valsartan as an anti-hypertensive treatment, effect on diuretic dosing and implementation of this novel compound in other populations. This review of recent literature identified important messages such as early initiation during index hospitalisation or immediately post-discharge, barriers against implementation of this novel treatment modality, analytical issues regarding measuring natriuretic peptides in patients under treatment and extrapolated use of sacubitril/valsartan in other than PARADIGM-HF populations. This update may serve as a very helpful evidence-based resource for practising clinicians, future research planning and health-related policy makers.

References

Dec 22, 2017·Pharmacotherapy·Kristin R SmithJo E Rodgers
Jun 28, 2018·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Christina E Sheppard, Maria Anwar
Nov 13, 2018·The New England Journal of Medicine·Eric J VelazquezUNKNOWN PIONEER-HF Investigators
Dec 12, 2018·Journal of Electrocardiology·Francisco J Pastor-PérezDomingo A Pascual-Figal
Dec 13, 2018·Journal of Cardiovascular Pharmacology·Amy X DuJustin A Ezekowitz
Dec 13, 2018·Journal of Cardiovascular Pharmacology·Lourdes VicentManuel Martínez-Sellés
Dec 28, 2018·Circulation·Duk-Hyun KangJae-Joong Kim
Feb 12, 2019·European Journal of Heart Failure·Orly VardenyScott D Solomon
Feb 21, 2019·Journal of the American College of Cardiology·Michael R ZileJean Rouleau
Feb 23, 2019·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Pieter MartensWilfried Mullens
Feb 24, 2019·Irish Journal of Medical Science·Aidan DalyRichard Liston
Mar 2, 2019·Cardiovascular Drugs and Therapy·Carles Moliner-AbósEulàlia Roig
Mar 6, 2019·Cardiology Research·Renato De VecchisCarmelina Ariano
Mar 6, 2019·European Journal of Heart Failure·Naveen L PereiraAllan S Jaffe
Mar 9, 2019·Journal of the American College of Cardiology·Peder Langeland MyhreScott D Solomon
Mar 12, 2019·Journal of Cardiovascular Pharmacology·Giuseppe PintoGabriele Fragasso
Mar 15, 2019·Cardiology·Lourdes VicentManuel Martinez-Sellés
Mar 23, 2019·Journal of the American College of Cardiology·Nasrien E IbrahimJames L Januzzi
Apr 12, 2019·European Journal of Heart Failure·Rolf WachterKarel Kostev
Apr 19, 2019·Cardiology·Lourdes VicentManuel Martínez-Sellés
Apr 28, 2019·Nefrología : publicación oficial de la Sociedad Española Nefrologia·Borja QuirogaVicente Álvarez-Chiva
May 13, 2019·JACC. Heart Failure·Craig BalmforthJohn J V McMurray
May 16, 2019·World Journal for Pediatric & Congenital Heart Surgery·Gentian LluriJamil Aboulhosn
Jun 7, 2019·Journal of Cardiovascular Medicine·Gloria SantangeloStefano Carugo
Jun 21, 2019·Expert Review of Pharmacoeconomics & Outcomes Research·Margarida BorgesJoão Costa

❮ Previous
Next ❯

Citations

Oct 10, 2020·Journal of the American College of Cardiology·Michele EmdinMichele Senni

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Related Papers

The Lancet. Diabetes & Endocrinology
Dayana FloresChristian Mueller
The Lancet. Diabetes & Endocrinology
Nicolas VodovarDamien Logeart
The Lancet. Diabetes & Endocrinology
Maya Guglin
The Lancet. Diabetes & Endocrinology
Jelena P SeferovicPARADIGM-HF investigators
© 2022 Meta ULC. All rights reserved